<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04811625</url>
  </required_header>
  <id_info>
    <org_study_id>PL-ASA-010</org_study_id>
    <nct_id>NCT04811625</nct_id>
  </id_info>
  <brief_title>Pharmacodynamic and Pharmacokinetic Study of PL-ASA</brief_title>
  <official_title>A Randomized, Open-label, 2-way Crossover Pharmacodynamic and Pharmacokinetic Study of a Novel Pharmaceutical Lipid-aspirin Complex Formulation (PL-ASA) at an 81 mg Dose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PLx Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PLx Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, open-label, 2-way crossover pharmacodynamic and pharmacokinetic study of a&#xD;
      novel pharmaceutical lipid-aspirin complex formulation (PL-ASA) at an 81 mg dose&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, open-label, 2-way crossover study to assess pharmacodyamic and&#xD;
      pharmacokinetic profiles following treatment with PL-ASA and EC-ASA administered under&#xD;
      fasting condition at a single dose of 81 mg among the volunteers aged 50 to 75 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 28, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Actual">September 15, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum thromboxane B2</measure>
    <time_frame>24 hours after dosing</time_frame>
    <description>Incidence of aspirin responsiveness among study participants, measured by inhibition of serum thromboxane B2 and thromboxane B2 levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acetylsalicylic acid and salicylic acid</measure>
    <time_frame>24 hours after dosing</time_frame>
    <description>Presence of serum acetylsalicylic acid and salicylic acid</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Light transmittance aggregometry</measure>
    <time_frame>24 hours after dosing</time_frame>
    <description>Effects on platelet function by light transmittance aggregometry</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse effects</measure>
    <time_frame>24 hours after dosing</time_frame>
    <description>Safety, as indicated by any adverse effects</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>PL-ASA capsule, then EC-ASA tablet</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>PL-ASA capsule 81 mg, then crossover to EC-ASA tablet 81 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EC-ASA tablet, then PL-ASA capsule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EC-ASA tablet 81 mg, then crossover to PL-ASA capsule 81 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PL-ASA</intervention_name>
    <description>Pharmacologic profile of different aspirin formulations</description>
    <arm_group_label>EC-ASA tablet, then PL-ASA capsule</arm_group_label>
    <arm_group_label>PL-ASA capsule, then EC-ASA tablet</arm_group_label>
    <other_name>Enteric-coated Aspirin (EC-ASA)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female non-smoking subjects between the ages of 50 to 75 years inclusive,&#xD;
             without known medical conditions requiring treatment&#xD;
&#xD;
          -  Consumes on average no more than 2 alcoholic drinks per day for 30 days prior to study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Abnormal baseline laboratory results&#xD;
&#xD;
          -  Current prescribed use of aspirin, warfarin or other anticoagulants&#xD;
&#xD;
          -  Use of other specific medications within 2 weeks of study start&#xD;
&#xD;
          -  History of certain medical conditions&#xD;
&#xD;
          -  Subject's platelets are unresponsive to arachidonic acid, as defined as &lt;60% of&#xD;
             aggregation as measured by light transmittance aggregometry&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Franchi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida C</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 19, 2021</study_first_submitted>
  <study_first_submitted_qc>March 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2021</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

